Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 18;16(1):318.
doi: 10.1186/s13018-021-02474-7.

Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Filippo Migliorini  1 , Nicola Maffulli  2   3   4 , Filippo Spiezia  5 , Markus Tingart  6 , Peretti Giuseppe Maria  7   8 , Giorgino Riccardo  8
Affiliations

Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Filippo Migliorini et al. J Orthop Surg Res. .

Abstract

Background: Biochemical markers of bone turnover (BTMs), such as bone alkaline phosphatase (bALP), procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary cross-linked N-telopeptides of type I collagen (NTx), are commonly used for therapy monitoring purposes for osteoporotic patients. The present study evaluated the potential role of BTMs as therapy monitoring.

Methods: All randomized clinical trials (RCTs) comparing two or more pharmacological treatments for postmenopausal osteoporosis were accessed. Only studies that reported the value of bALP, PINP, bCTx, and NTx at last follow-up were included. A multivariate analysis was performed to assess associations between these biomarkers and clinical outcomes and rate of adverse events in patients with postmenopausal osteoporosis. A multiple linear model regression analysis through the Pearson product-moment correlation coefficient was used.

Results: A total of 16 RCTs (14,446 patients) were included. The median age was 67 years, and the median BMI 25.4 kg/m2. The median vertebral BMD was 0.82, hip BMD 0.79, and femur BMD 0.64 g/cm2. The ANOVA test found optimal within-group variance concerning mean age, body mass index, and BMD. Greater bALP was associated with lower femoral BMD (P = 0.01). Greater NTx was associated with a greater number of non-vertebral fractures (P = 0.02). Greater NTx was associated with greater rate of therapy discontinuation (P = 0.04). No other statistically significant associations were detected.

Conclusion: Our analysis supports the adoption of BTMs in therapy monitoring of osteoporotic patients.

Level of evidence: Level I, systematic review of RCTs.

Keywords: Biomarkers; Osteoporosis; Postmenopausal; Therapy monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Flow chart of the literature search
Fig. 2
Fig. 2
Methodological quality assessment
Fig. 3
Fig. 3
Added variable plots of the statistically significant outcomes
See this image and copyright information in PMC

References

    1. Florencio-Silva R, Sasso GR, Sasso-Cerri E, et al. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015;2015:421746. doi: 10.1155/2015/421746. - DOI - PMC - PubMed
    1. Hill PA. Bone remodelling. Br J Orthod. 1998;25:101–107. doi: 10.1093/ortho/25.2.101. - DOI - PubMed
    1. Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem. 2014;51:189–202. doi: 10.1177/0004563213515190. - DOI - PubMed
    1. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997;30:573–593. doi: 10.1016/S0009-9120(97)00113-6. - DOI - PubMed
    1. Samoszuk M, Leuther M, Hoyle N. Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomark Med. 2008;2:495–508. doi: 10.2217/17520363.2.5.495. - DOI - PubMed

Publication types

MeSH terms